Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
Prospective observational study to IDEntify patients with advanced/metastatic NSCLC and ALK and ROS1 translocation and to establish their therapeutic management (IDEALK&ROS)
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
-
Patients with Advanced or metastatic non-small cell lung cancer
-
Patients who will be screened for anaplastic lymphoma kinase (ALK) rearrangement
-
Age > 18 years
-
For the patients that will be recruited prospectively: Patients must have a signed informed consent document.
-
For the treatment sub-study, patients must also meet the following criteria
- Confirmed anaplastic lymphoma kinase (ALK)-positive tumour
- Patients treated with crizotinib under routine clinical practice
- Patients with a minimum data registered at the medical history
For the ROS1 treatment sub-study:
- Confirmation of NSCLC with ROS1-positive translocation
- Have been eligible to receive treatment with crizotinib according to routine clinical practice since the market launch of the ROS1 indication in Spain on 8 February 2017 until the opening of the site.
- Patients should have a predetermined minimum amount of data recorded in their medical records.
Exclusion criteria
- Any patient who does not meet any of the inclusion criteria defined in the previous section, depending on the sub-study for which they are included.
Trial design
141 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal